ReNeuron (LON:RENE) has received a Notice of Allowance from the US Patent and Trademark Office for a key patent application covering its cell cryopreservation technology.
The patent application contains broad claims relating to cryopreserved neural, retinal and mesenchymal stem cells using a formulation developed by ReNeuron that is free of toxic cryopreservants.
ReNeuron is using cryopreservation technology in its CTX stem cell line to derive a cryopreserved, long shelf life cell therapy candidate, designated CTXcryo.
Ongoing UK clinical trials in both stroke disability and critical limb ischaemia include the technology.
Olav Hellebø, ReNeuron’s chief executive added the company had invested heavily in patents in recent and the US Notice of Allowance for cell cryopreservation was another important addition.